Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated:
June 15, 2022
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Acute myeloid leukemia (AML), Maintenance therapy in adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)
Last updated:
June 7, 2022
Status:
Concluded without agreement
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
June 1, 2022
Status:
Concluded without agreement
Manufacturer:
HLS Therapeutics Inc.
Indication:
Schizophrenia
Last updated:
June 1, 2022
Status:
Concluded without agreement
Manufacturer:
M�dunik Canada Inc.
Indication:
Lambert-Eaton Myasthenic Syndrome (LEMS)
Last updated:
June 1, 2022
Phesgo SC (perjeta and herceptin)
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic breast cancer (HER2-positive) first-line treatment
Last updated:
May 19, 2022
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Extensive-stage small cell lung cancer (ES-SCLC) in adult patients, first-line treatment (in combination with etoposide and either carboplatin or cisplatin)
Last updated:
May 18, 2022
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated:
May 17, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated:
May 16, 2022
Status:
Concluded with an LOI
Manufacturer:
Organon Canada Inc.
Indication:
Metastatic breast cancer (HER2-positive) in patients with who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)
Last updated:
May 16, 2022